MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data

Phase 3negativeTrodelvyKeytrudaNegative

AI Analysis

Summary

MSD and Gilead have terminated a Phase III trial combining Trodelvy and Keytruda due to disappointing interim data, marking a setback for Gilead's Trodelvy expansion strategy.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Phase III study terminated due to lacklustre interim data

Importance:7/10

Sentiment:

-0.80

Phase 3 terminationcombination therapytrial failureTrodelvyKeytruda

Related Companies

$GILD

Read the original article

Published by Clinical Trials Arena on August 6, 2026 10:04 AM

Read Original